H107e/CAF10b
H107e/CAF®10b is being developed by SSI and is a next-generation TB subunit vaccine incorporating 8 different Mtb antigens in a novel liposomal Th1/Th17 inducing adjuvant. It is specifically designed to complement a BCG response with novel T cells against Mtb-specific antigens and comes with the option of BCG co-administration.
Read MoreBCGΔBCG1419c
This is a second-generation version of BCGΔBCG1419c, devoid of antibiotic markers. It is based on BCG Pasteur ATCC 35734.
Read MoreM72/AS01E
The M72/AS01E vaccine candidate consists of the M72 fusion protein and the proprietary GSK adjuvant system AS01E.
Read MoreChAdOx1.85A+MVA85A*
ChAdOx1.85A is a simian adenoviral vector expressing Antigen 85A. MVA85A is a modified vaccinia virus Ankara expressing Antigen 85A. The target route of administration for ChAdOx1.85A is aerosol, and intramuscular for MVA85A.
Read More